
Abbott Laboratories
- Jurisdiction
United States - LEI
HQD377W2YR662HK5JX27 - ISIN
US0028241000 (ABT )- Sectors
Scores
- Fair value (Benjamin Graham formula)
-
€42.68 158.3% overvalued - Financial strength (Piotroski F-Value)
-
7
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
1
/ 7
Profile
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. Read full profile
Stock price
Fundamentals
- Net revenue
€36.99B - Gross margin
56.1% - EBIT
€6.49B - EBIT margin
17.5% - Net income
€11.99B - Net margin
32.4%
Statement period: - (published )
Estimates
Fiscal Year | Net revenue | Net income |
---|---|---|
|
| |
|
| |
|
|
Dividends
- Last dividend amount
-
$0.59 - Ex date
-
- Payment date
-
- Dividend payout ratio
-
28.4%
Insider Transactions
Name | Title | Transaction Date | Shares | Price | Value |
---|---|---|---|---|---|
Boudreau Philip P | EVP AND CFO |
|
|
|
|
Congress transactions
Name | Transaction date | Value |
---|---|---|
Rick Larsen | October 16, 2025 | $1.00K–$15.00K |
Richard McCormick | September 17, 2025 | $1.00K–$15.00K |
Julie Johnson | September 11, 2025 | $1.00K–$15.00K |
Thomas Kean | August 20, 2025 | $1.00K–$15.00K |
Lisa McClain | August 13, 2025 | $1.00K–$15.00K |
Earnings Calls
Latest earnings call: July 17, 2025
Investor transactions
Name | Shares | Value | Last change | Change type |
---|---|---|---|---|
Ray Dalio |
|
|
|
Sell |
Nancy Zevenbergen |
|
|
|
Buy |